Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations.

Revive Therapeutics Ltd. CSE: RVV | USA: RVVTF

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Learn more: https://bit.ly/3FAoFmA 

$RVV $RVVTF #Bucillamine #Infectiousdiseases #Covid19 #OmicronVarient #DeltaVariant #ClinicalTrials #FDA #clinicaltrial

4 Life Sciences Companies Hit the Ground Running in 2022

Learn more: https://bit.ly/3ERmV7Y

$RVV $RVVTF #Bucillamine #covid19

Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs

IRB approval to initiate Phase 2 study for #methamphetamine abuse disorders

Advancing psilocybin oral thin film, microneedle patch and biosynthesis programs

Learn More: https://bit.ly/3KhMEuk

$RVV $RVVTF #psychedelics #psilocybin #microneedle #mentalwellness #clinicalstudy

Revive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19

Learn more: https://bit.ly/3JNILwR 

$RVV $RVVTF #Bucillamine #Infectiousdiseases #Covid19 #OmicronVarient #DeltaVariant #ClinicalTrials

4 Life Sciences Companies Hit the Ground Running in 2022

Read more: https://bit.ly/3ERmV7Y 

$RVV $RVVTF #Bucillamine #covid19

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Learn More: https://bit.ly/3EEZNd5 

$RVV $RVVTF #Bucillamine #Infectiousdiseases #Covid19 #OmicronVarient #DeltaVariant #ClinicalTrials

PCORI Biweekly COVID-19 Scan: Bucillamine - Oral Anti-Inflammatory Drug, Direct-to-consumer Telehealth Platforms (November 25-December 5, 2021)

Learn more: https://bit.ly/3JgFZzX 

#Bucillamine #COVID19

The Second Wave: Biopharma Players Race to Develop Therapeutics for COVID-19

Read more: https://bit.ly/3yF9CGj

$RVV $RVVTF #COVID19 #Bucillamine

Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial

Learn more: https://bit.ly/3rzk6FW 

$RVV $RVVTF #Bucillamine #Infectiousdiseases #Covid19 #OmicronVarient #DeltaVariant #ClinicalTrials

Revive Therapeutics Files for FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation

Read more: https://bit.ly/30ThoQw 

$RVV $RVVTF #Bucillamine #FDA #orphandrugstatus #livertransplant #IRI

Viewport Meta

IPhone / Mobile Compatible

SSL by Default

Euro

Google Tag Manager

Apple Mobile Web Clips Icon

HSTS

Google Font API

WordPress

Global Site Tag

Chief Operating Officer Psilocin Pharma Corp a Division of Revive Therapeutics

Derrick Welsh

Healthcare

Emily Brelsford

Business Management

Lauren Laurent

Rumyana Hristova

Michael Frank

Founder&CEO

Doug Cowart

Emily Han

Director of Clinical Operations / Founding Member

Pharmaceutical Public Companies With Fewer Than 1000 Employees

Cannabis Companies With More Than $1M in Revenue

Great Lakes Companies With Less Than $10M in Revenue (Top 10K)

Great Lakes Companies that Exited (Top 10K)

Revive Therapeutics Ltd. (TSX-V: RVV) (OTCQB: RVVTF) (FSE: 31R) is focused on the research, development and commercialization of novel therapies and technologies for the medical cannabis and cannabinoid pharmaceuticals markets by identifying and investigating potential therapies targeting the endocannabinoid system, such as cannabinoids, that may be repurposed for new indications, be delivered in a different way, combined with existing drugs, or be developed as new chemical entities.

Post-IPO Equity - Revive Therapeutics

EMD Financial

Vaughan

Ontario

Canada

North America

Revive Therapeutics

Revive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product

Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

Revive announces completion of rights offering

Revive Therapeutics Appoints Dr. Scott Friedman, MD, as Scientific Advisor for Cannabinoid-Based Therapeutics ...

Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat ...

Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product

An oral thiol-based drug being developed for the treatment of COVID-19, long COVID, and other infectious diseases, as well as rare inflammatory disorders.

Therapeutics using psilocybin for the treatment of mental illnesses such as depression and anxiety, and substance use disorders like methamphetamine use disorder.

A point-of-care in vitro diagnostic device for detecting post-COVID-19 conditions using blood biomarkers.

Therapeutics using CBD for the treatment of autoimmune hepatitis and the prevention of ischemia and reperfusion injury in organ transplantation.

United States

The Netherlands

Europe

India

Asia

Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. Revive Therapeutics Ltd. has research collaboration agreements with PharmaTher Inc. for the development of psilocybin in the treatment of cancer and the discovery of other uses of undisclosed psychedelic compounds; North Carolina State University for the development of a biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform; the University of California, San Francisco to explore the use of Bucillamine as a treatment for severe COVID-19; University of Health Sciences Antigua for the clinical research of psychedelics; and PharmaTher for the development of psilocybin microneedle patch. The company was incorporated in 2012 and is headquartered in Toronto, Canada.

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 22, 2024 7:44 AM	f34405ee
crunchbase profile	general	Nov 22, 2024 9:05 AM	e1036891
li profile	general	Feb 1, 2024 12:33 AM	b529f8e1
translate crunchbase fundingrounds	general	Nov 22, 2024 1:53 PM	8f5dbc97
peers	general	Feb 1, 2024 12:33 AM	f4d4db68
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

RVV

COM:REVIVETHERA

Revive Therapeutics Ltd.

Last Close

0.01

22/11 20:58

Market Cap

3.58M

Beta: -

Volume Today

45K

Avg: -